Clinical Trials Sponsored by FKD Therapies Oy

Total 4 results

FKD Therapies Oy

Completed

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Superficial Bladder Cancer
Ferring Pharmaceuticals
FKD Therapies Oy; Society of Urologic Oncology Clinical Trials Consortium

Completed

ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Superficial Bladder Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); FKD Therapies Oy of Finland

Completed

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

Bladder Cancer

United States
Kuopio University Hospital
Medical University of Vienna; Rigshospitalet, Denmark; University College, London and other collaborators

Active, not recruiting

Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris (ReGenHeart)

Coronary Artery Disease | Refractory Angina Pectoris | Gene Transfer

Denmark, Finland

3

Subscribe